Nature Reviews Drug Discovery

Amylin takes another shot at the obesity prize

Asher Mullard Jun 01, 2025 pp. 403-406 10.1038/d41573-025-00088-w

Is the FDA’s plan to phase out animal toxicity testing realistic?

Asher Mullard Jun 01, 2025 pp. 413-414 10.1038/d41573-025-00087-x

FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor

Asher Mullard Jun 01, 2025 pp. 408-408 10.1038/d41573-025-00086-y

Hinge modifier approach opens door to drugging HECT E3 ligases

Alex Eccleston Jun 01, 2025 pp. 417-417 10.1038/d41573-025-00084-0

A liver-directed route to reverse allergies

M. Teresa Villanueva Jun 01, 2025 pp. 419-419 10.1038/d41573-025-00083-1

FDA approves J&J’s FcRn blocker for generalized myasthenia gravis

Asher Mullard Jun 01, 2025 pp. 407-407 10.1038/d41573-025-00081-3

FDA approves cell-sheet-based gene therapy for severe skin disease

Asher Mullard Jun 01, 2025 pp. 407-407 10.1038/d41573-025-00082-2

Understanding LAG3 immune checkpoint function

Sarah Crunkhorn Jun 01, 2025 pp. 420-420 10.1038/d41573-025-00076-0

Ramping up mitochondrial DNA replication

Katie Kingwell Jun 01, 2025 pp. 419-419 10.1038/d41573-025-00079-x

TIM-3 regulates microglial function

Sarah Crunkhorn Jun 01, 2025 pp. 420-420 10.1038/d41573-025-00078-y

Lasso peptide targets drug-resistant bacteria

Sarah Crunkhorn Jun 01, 2025 pp. 420-420 10.1038/d41573-025-00075-1

Targeting RNA structure to treat prostate cancer

Sarah Crunkhorn Jun 01, 2025 pp. 420-420 10.1038/d41573-025-00077-z

New antifungal tackles drug-resistant infections

Sarah Crunkhorn Jun 01, 2025 pp. 418-418 10.1038/d41573-025-00074-2

Enzymes in secondary pharmacology screening panels: is there room for improvement?

Monika Maciag, Vardan T. Karamyan Jun 01, 2025 pp. 480-481 10.1038/s41573-025-01173-w

Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels

Friedemann Schmidt, Richard J. Brennan, Steve Jenkinson et al. Jun 01, 2025 pp. 482-484 10.1038/s41573-025-01184-7

Analysis of China-to-West pharmaceutical licensing deals in 2024

Leon ‘Jun’ Tang Jun 01, 2025 pp. 411-412 10.1038/d41573-025-00068-0

Trends in the drug target landscape for autoimmune diseases

Alexandre Fauconnier, Marie Melis, Marc Berenbeck et al. Jun 01, 2025 pp. 415-416 10.1038/d41573-025-00061-7

Life science ecosystems in Asia: biomedical innovation trends over the past decade

Ajay Gautam Jun 01, 2025 pp. 409-410 10.1038/d41573-025-00041-x

Accelerating adoption of new approach methodologies in regulatory decision making: an industry perspective

Andrew S. Robertson, Nahid Latif, Imein Bousnina et al. Jun 01, 2025 pp. 401-402 10.1038/d41573-025-00038-6

Thirty years of NRF2: advances and therapeutic challenges

Donna D. Zhang Jun 01, 2025 pp. 421-444 10.1038/s41573-025-01145-0

GPCR drug discovery: new agents, targets and indications

Javier Sánchez Lorente, Aleksandr V. Sokolov, Gavin Ferguson et al. Jun 01, 2025 pp. 458-479 10.1038/s41573-025-01139-y

MYC in cancer: from undruggable target to clinical trials

Jonathan R. Whitfield, Laura Soucek Jun 01, 2025 pp. 445-457 10.1038/s41573-025-01143-2